Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells

被引:463
作者
Hanenberg, H
Xiao, XL
Dilloo, D
Hashino, K
Kato, I
Williams, DA
机构
[1] INDIANA UNIV, SCH MED, SECT PEDIAT HEMATOL ONCOL, JAMES WHITCOMB RILEY HOSP CHILDREN, INDIANAPOLIS, IN 46202 USA
[2] ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38101 USA
[3] TAKARA SHUZO CO LTD, BIOTECHNOL RES LABS, OTSU, SHIGA 52021, JAPAN
[4] INDIANA UNIV, SCH MED, HOWARD HUGHES MED INST, INDIANAPOLIS, IN 46202 USA
关键词
D O I
10.1038/nm0896-876
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hematopoietic cells are important targets for genetic modification with retroviral vectors. Attempts at human gene therapy of stem cells have achieved limited success partly because of low gene transfer efficiency. Chymotryptic fragments of the extracellular matrix molecule fibronectin used during infection have been shown to increase transduction of human hematopoietic progenitor cells. Here, we demonstrate that this enhanced gene transfer into mammalian target cells is due to direct binding of retroviral particles to sequences within the fibronectin molecule. Transduction of mammalian cells, including murine long-term repopulating hematopoietic cells, is greatly enhanced when cells are adherent to chimeric fragments containing these retroviral binding sequences. In addition, colocalization of retrovirus and target cells on fibronectin peptides allows targeted transduction of specific cell types by exploiting unique ligand/receptor interactions.
引用
收藏
页码:876 / 882
页数:7
相关论文
共 39 条
  • [1] [Anonymous], 1996, B MED ETHICS
  • [2] T-LYMPHOCYTE-DIRECTED GENE-THERAPY FOR ADA(-) SCID - INITIAL TRIAL RESULTS AFTER 4 YEARS
    BLAESE, RM
    CULVER, KW
    MILLER, AD
    CARTER, CS
    FLEISHER, T
    CLERICI, M
    SHEARER, G
    CHANG, L
    CHIANG, YW
    TOLSTOSHEV, P
    GREENBLATT, JJ
    ROSENBERG, SA
    KLEIN, H
    BERGER, M
    MULLEN, CA
    RAMSEY, WJ
    MUUL, L
    MORGAN, RA
    ANDERSON, WF
    [J]. SCIENCE, 1995, 270 (5235) : 475 - 480
  • [3] BODINE DM, 1991, EXP HEMATOL, V19, P206
  • [4] GENE-THERAPY IN PERIPHERAL-BLOOD LYMPHOCYTES AND BONE-MARROW FOR ADA(-) IMMUNODEFICIENT PATIENTS
    BORDIGNON, C
    NOTARANGELO, LD
    NOBILI, N
    FERRARI, G
    CASORATI, G
    PANINA, P
    MAZZOLARI, E
    MAGGIONI, D
    ROSSI, C
    SERVIDA, P
    UGAZIO, AG
    MAVILIO, F
    [J]. SCIENCE, 1995, 270 (5235) : 470 - 475
  • [5] FIBRONECTIN TYPE-III MODULES IN THE RECEPTOR PHOSPHATASE CD45 AND TAPEWORM ANTIGENS
    BORK, P
    DOOLITTLE, RF
    [J]. PROTEIN SCIENCE, 1993, 2 (07) : 1185 - 1187
  • [6] BRADLEY TR, 1979, BLOOD, V54, P1446
  • [7] GENE MARKING TO DETERMINE WHETHER AUTOLOGOUS MARROW INFUSION RESTORES LONG-TERM HEMATOPOIESIS IN CANCER-PATIENTS
    BRENNER, MK
    RILL, DR
    HOLLADAY, MS
    HESLOP, HE
    MOEN, RC
    BUSCHLE, M
    KRANCE, RA
    SANTANA, VM
    ANDERSON, WF
    IHLE, JN
    [J]. LANCET, 1993, 342 (8880) : 1134 - 1137
  • [8] CLAPP DW, 1995, EXP HEMATOL, V23, P630
  • [9] DALTON SL, 1992, J BIOL CHEM, V267, P8186
  • [10] GENETIC MARKING SHOWS THAT PH(+) CELLS PRESENT IN AUTOLOGOUS TRANSPLANTS OF CHRONIC MYELOGENOUS LEUKEMIA (CML) CONTRIBUTE TO RELAPSE AFTER AUTOLOGOUS BONE-MARROW IN CML
    DEISSEROTH, AB
    ZU, ZF
    CLAXTON, D
    HANANIA, EG
    FU, SQ
    ELLERSON, D
    GOLDBERG, L
    THOMAS, M
    JANICEK, K
    ANDERSON, WF
    HESTER, J
    KORBLING, M
    DURETT, A
    MOEN, R
    BERENSON, R
    HEIMFELD, S
    HAMER, J
    CALVERT, L
    TIBBITS, P
    TALPAZ, M
    KANTARJIAN, H
    CHAMPLIN, R
    READING, C
    [J]. BLOOD, 1994, 83 (10) : 3068 - 3076